Ensitrelvir shows 67% reduction in COVID-19 risk in trial
In a phase 3 SCORPIO-PEP trial published on September 26, 2026, Shionogi’s oral antiviral ensitrelvir demonstrated a 67% reduction in symptomatic COVID-19. Participants took the drug within 72 hours of exposure, resulting in 2.9% symptomatic incidence compared to 9.0% on placebo. High-risk participants experienced a 76% risk reduction. The drug is currently under FDA priority review with a decision expected by June 2026.
Shionogi’s experimental oral antiviral, ensitrelvir, has reduced the risk of symptomatic COVID-19 in a phase 3 clinical trial known as SCORPIO-PEP. Published on September 26, 2026, in the New England Journal of Medicine, the study found a 67% relative risk reduction for those who took the drug within 72 hours of being exposed at home. Only 2.9% of participants treated with ensitrelvir developed symptoms, whereas 9.0% of the placebo group became ill. These results suggest ensitrelvir could play a major role in managing the virus, particularly for vulnerable groups.
Researchers designed SCORPIO-PEP to test how well ensitrelvir prevents symptoms after a person has been exposed. The resulting data is substantial and supports the use of the drug in everyday settings. Among high-risk participants, the benefit was even more pronounced, with a 76% reduction in risk. This level of protection offers a new treatment path as the global response to the pandemic continues.
The trial included a diverse range of people from various backgrounds and health histories. Success depended on close cooperation between researchers, healthcare providers, and the participants themselves to ensure the data remained accurate. The findings also underscore why timing matters; starting treatment quickly after exposure can change how the disease progresses in people who are most at risk.
Beyond the benefits to individual patients, ensitrelvir could have a wider impact. By lowering the number of symptomatic cases, the drug might ease the burden on hospitals and support broader immunity efforts. This remains a priority as countries deal with new variants and the ongoing complexities of vaccination. Reducing the likelihood of severe illness and hospitalization marks a step forward for public health strategy.
The FDA is currently putting ensitrelvir through a priority review, with a final decision expected by June 2026. If it receives approval, the drug could become a standard resource for protecting those at the highest risk of severe COVID-19. These trial results represent progress in antiviral therapy and highlight the necessity of steady research and development to meet global health needs.
Enjoyed this story?
Show the newsroom a little love — one tap per reader.
Aisha travels the world collecting stories of everyday kindness and quiet courage.
Be part of the good
Stories like this start with people who care. Share it, or submit your own uplifting story to inspire millions today.
